Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Assets for 4 consecutive years, with $507.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 12.86% to $507.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $507.8 million, a 12.86% decrease, with the full-year FY2025 number at $507.8 million, down 12.86% from a year prior.
  • Assets was $507.8 million for Q4 2025 at Day One Biopharmaceuticals, down from $513.8 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $600.8 million in Q3 2024 to a low of $267.8 million in Q1 2022.
  • A 4-year average of $434.6 million and a median of $409.1 million in 2022 define the central range for Assets.
  • Biggest YoY gain for Assets was 63.59% in 2025; the steepest drop was 14.49% in 2025.
  • Day One Biopharmaceuticals' Assets stood at $349.1 million in 2022, then grew by 7.73% to $376.0 million in 2023, then skyrocketed by 54.98% to $582.8 million in 2024, then dropped by 12.86% to $507.8 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Assets are $507.8 million (Q4 2025), $513.8 million (Q3 2025), and $519.0 million (Q2 2025).